Molto probabilmente questo è legato a questo """""" OBJ Limited...

Originariamente pubblicato da ahpigsy

Quindi dalla dicitura Acquisizione materiale sappiamo che è in corso un acquisto. Ma significa che OBJ sta facendo l'acquisto? Perché dovremmo andare in sospensione se OBJ controlla l'acquisto? La dicitura potrebbe anche significare che qualcuno vuole acquistare qualcosa da noi?

Ok, quindi ho intenzione di gettare qualcosa là fuori. Sognando !!! P&G potrebbe voler assicurarsi l'accordo tecnologico con noi semplicemente acquistandoci prima che la "squadra olimpica" renda il prezzo troppo costoso per loro? Ecco qua la mia fantasia per il giorno.

Molto probabilmente questo è legato a questo """""" OBJ Limited (ASX: OBJ) is pleased to announce that it has signed an agreement with Little
Green Pharma (LGP), the only Australian producer and supplier of GMP quality medicinal
cannabis products, to explore the adaptation of OBJ’s transdermal technology for the delivery
of cannabinoid therapy.
Under the funding and option agreement OBJ and LGP will collaborate on the project along
with research and development experts at Curtin University. It also includes proposed joint
funding of the R&D activities as well as establishing a formal 50:50 joint venture for the
ownership and commercialisation of cannabis and transdermal technologies in the event of
successful trials.
Unique Strategic Opportunity – Medicinal Cannabis and OBJ’s Proprietary
Transdermal (Patch) Technology
With the global legal cannabis market projected to hit $232 billion by 2027¹, one of the key
focuses of major players in the space is cannabinoid delivery systems. Current and emerging
cannabinoid delivery systems include vaping, tablets, capsules, chewing gums, oils and non
diamagnetic patches. Many of these are limited in their ability to deliver an accurate dose,
when and where needed, and not be impacted by first pass metabolism in the case of anything
ingested or inhaled.
OBJ currently uses its proven, patent protected diamagnetic microarray technology in both
skin care and joint inflammation products. The technology assists in the transporting of key
ingredients across the skin and into the tissue or bloodstream of a targeted area. Compared to
normal patches which rely solely on formulation, the OBJ technology helps push the large
sized molecules through skin, which have difficulty penetrating the skin when relying on
absorption alone. In effect you can deliver the drug far more effectively to the ‘problem area’
which means far greater control of dosage, time of onset and effectiveness. OBJ’s patented
microarray technology has already been sold in over a million skin care devices by Procter
and Gamble (P&G).
If the cannabinoid trials at Curtin University are successful in demonstrating that
cannabinoids can effectively use OBJ’s microarray technology:
(a) this could result in one of the most advanced and effective medicinal cannabis
delivery systems developed in the world, to date; and

(b) the OBJ joint venture with LGP could rapidly develop both its own products as well
as licensing the technology to third parties for rapid distribution worldwide. LGP
operates from one of the few fully-licensed GMP certified medicinal cannabis
manufacturing facilities in Australia.
Little Green Pharma was the first – and is currently the only – Australian medicinal cannabis
company producing locally-grown and GMP-manufactured cannabis products for patients.
Little Green Pharma cultivates locally grown medicinal cannabis from a secure facility in
Western Australia.